	KINTAMPO HEALTH RESEARCH CENTRE(KHRC)



You are here: Home--:>RTS,S study

	First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months. Posted: 28 October, 2011 ◊ Print this story The initial results from a large-scale Phase III study of the malaria vaccine called RTS,S, were published online on 18th October, 2011 in the New England Journal of Medicine (NEJM). The results showed that the malaria vaccine candidate can provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington. USA. The malaria vaccine study is being conducted among two groups of children aged 5 -17 months and 6 -12 weeks old in 11 clinical trial centres located in seven African countries including the Kintampo Health Research Centre (KHRC), Brong Ahafo Region. The study was conducted to determine the efficacy and safety of the RTS,S malaria vaccine. Among the 5 to 17 month-old children, three doses of the malaria vaccine reduced the risk of experiencing clinical malaria and severe malaria by 56% and 47%, respectively. This analysis was performed on information gathered from the first 6,000 children aged 5 to 17 months involved in the study, over a 12-month period following vaccination. Clinical malaria results in fevers and chills and can rapidly develop into severe malaria, typified by serious effects on the blood, brain, or kidneys that can prove fatal. These first Phase III results are in line with those from previous Phase II studies. The study is ongoing among the 6 to 12 weeks old infants. The efficacy and safety results of these infants are expected by the end of 2012. The Director of KHRC Dr. Seth Owusu Agyei attended the malaria forum in the US. In Kintampo, a one day workshop was organised on 19th October, 2011 and this brought together stakeholders in the Kintampo North Municipality and the Kintampo South District. They included political and traditional authorities, departmental heads, the media, the Ghana Police Service, Civic and human rights organisations. The Co – Principal Investigator of the study at the KHRC, Dr. Kwaku Poku Asante briefed all present about the results of the study. He thanked them for the support given the KHRC in the conduct of this study. He encouraged them to continue to render their unflinching support for the study which is still ongoing. For more information please follow this link for the full press release(PDF): For more info contact: Kabio Casimir Donlebo (Communications Officer). Kintampo Health Research Centre P.O.Box 200 Kintampo.B/A. Tel: +233 246 391916	Translate into other language:
◊ Print this story
	Kintampo Health Research Centre

First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months.

Posted: 28 October, 2011 ◊ Print this story

Declaration of Results to stakeholders

The initial results from a large-scale Phase III study of the malaria vaccine called RTS,S, were published online on 18th October, 2011 in the New England Journal of Medicine (NEJM). The results showed that the malaria vaccine candidate can provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington. USA.

The malaria vaccine study is being conducted among two groups of children aged 5 -17 months and 6 -12 weeks old in 11 clinical trial centres located in seven African countries including the Kintampo Health Research Centre (KHRC), Brong Ahafo Region. The study was conducted to determine the efficacy and safety of the RTS,S malaria vaccine.

Among the 5 to 17 month-old children, three doses of the malaria vaccine reduced the risk of experiencing clinical malaria and severe malaria by 56% and 47%, respectively. This analysis was performed on information gathered from the first 6,000 children aged 5 to 17 months involved in the study, over a 12-month period following vaccination. Clinical malaria results in fevers and chills and can rapidly develop into severe malaria, typified by serious effects on the blood, brain, or kidneys that can prove fatal. These first Phase III results are in line with those from previous Phase II studies.

The study is ongoing among the 6 to 12 weeks old infants. The efficacy and safety results of these infants are expected by the end of 2012.

The Director of KHRC Dr. Seth Owusu Agyei attended the malaria forum in the US. In Kintampo, a one day workshop was organised on 19th October, 2011 and this brought together stakeholders in the Kintampo North Municipality and the Kintampo South District. They included political and traditional authorities, departmental heads, the media, the Ghana Police Service, Civic and human rights organisations. The Co – Principal Investigator of the study at the KHRC, Dr. Kwaku Poku Asante briefed all present about the results of the study. He thanked them for the support given the KHRC in the conduct of this study. He encouraged them to continue to render their unflinching support for the study which is still ongoing.

For more information please follow this link for the full press release(PDF):

For more info contact:

Kabio Casimir Donlebo (Communications Officer).
Kintampo Health Research Centre
P.O.Box 200
Kintampo.B/A.
Tel: +233 246 391916

Translate into other language:

◊ Print this story

Kintampo Health Research Centre